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Abstract
1.1. Background 
Preclinical studies suggest that the neuropeptide oxytocin reduces food intake and body weight, but only a few 
clinical studies have investigated the translatability of these findings in humans. The present study investigated the 
safety and efficacy of oxytocin nasal spray in patients affected by binge eating disorder and obesity. 
1.2. Methods 
Seventeen outpatients affected by binge eating disorder and obesity participated in a 8 week double-blind trial 
and received oxytocin (n=8; 24 IU, four times a day, 20 min before each of three meals and before going to bed) or 
placebo (n=9) with an energy-restricted diet. Primary outcomes included adverse events and the number of binge eating 
episodes per week. Secondary measures included body weight, BMI, severity of BED, craving for food, quality of sleep, 
quality of life, anxiety, and depressive symptoms. 
1.3. Results 
One patient of oxytocin group discontinued prematurely the trial before the first post-randomization efficacy measure. 
Among the other 16 participants, 13 (81.2%) completed the trial, and 3 (18.8%) discontinued [3 in the oxytocin group; 
0 in the placebo group (p=0.0625, Fisher’s exact test)]. No significant difference between groups was found in any 
outcome evaluated. Patients of the placebo group performed slightly better than patients of the oxytocin group in some 
secondary outcomes, but these differences were not significant.
1.4. Conclusion 
Oxytocin nasal spray resulted to be safe, including in women of childbearing age but did not significantly reduce the 
number of binge eating episodes per week in outpatients affected by binge eating disorder and obesity. These findings 
are discussed in light of the human oxytocin literature. 
Keywords: Oxytocin nasal spray; Obesity; Binge eating disorder; 
Body weight; Sex differences
Introduction
Binge eating disorder (BED) is a mental disorder characterized 
by recurrent consumption of an unusually large amount of food in 
a discreet period of time, accompanied by a sense of lack of control, 
without inappropriate compensatory behaviors typical of bulimia 
[1]. Consequently, BED is often associated with obesity and obese 
individuals with BED have a higher concern for body weight and body-
shape dissatisfaction than obese individuals without BED [2]. BED 
is also associated with significant psychiatric comorbidities, such as 
mood and anxiety disorders [1]. 
Pharmacologic agents (antidepressants, anticonvulsants, and 
obesity drugs) have shown moderate effectiveness for the treatment of 
BED and the only medication approved in the US, but not in Europe, 
is a prodrug of dextroamphetamine, lisdexamfetamina dimesylate [3]. 
In the last 20 years, knowledge regarding the central and peripheral 
mechanisms controlling food intake, energy balance, metabolism, and 
related aspects, such as appetite and satiety, has greatly increased and 
numerous neurotransmitters, neuropeptides, and hormones involved 
in these mechanisms have been identified [4]. Interestingly, a large body 
of findings supports a prominent role for oxytocin in the modulation of 
food intake and body weight in animal models [5]. 
Oxytocin is a neuropeptide primarily produced in the supraoptic 
(SON) and paraventricular (PVN) hypothalamic nuclei and released 
by the neurohypophysis into the bloodstream for its hormonal effects 
in lactation and uterine contractions [6]. Hypothalamic oxytocinergic 
neurons also project to specific central areas involved in the modulation 
of motivation, sense of well-being, and sexual performance [6,7]. A 
large number of studies found that administration of oxytocin reduces 
food intake and body weight in animal models of obesity [5,8]. 
Only a few studies have investigated the role of oxytocin in human 
nutrition [9-12]. In the first study, intravenous administration of 
oxytocin to healthy subjects reduced, instead of increasing, the sensation 
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Study Design
The study was a pilot 8 week, outpatient, randomized, double-
blind trial. The trial consisted of the following phases: (1) a 2 week 
screening period; (2) a 8 week double-blind treatment period; and (3) a 
1 week treatment discontinuation period. Patients were evaluated twice 
during the screening period, three times during the pharmacologic 
treatment (after 1, 4 and 8 weeks), and once one week after medication 
discontinuation.
During the screening period, patients were interviewed to collect 
demographic and clinical information and submitted to a physical 
examination during which vital signs, height, and weight were 
measured and the BMI was calculated. Then, blood chemical and 
hematologic tests were requested. Women of childbearing age were 
given a urine pregnancy test. Only patients with normal blood chemical 
and hematologic tests and negative pregnancy tests were eligible for 
the psychiatric visit. One week later, patients were submitted to the 
psychiatric visit during which the diagnosis of BED and co-morbid 
mental disorders were investigated using the Structured Clinical 
Interview for DSM-IV, Axis I Disorders (SCID-I). Patients who 
satisfied the inclusion and exclusion criteria were asked to take part 
in the study, and to sign the written informed consent forms. Then, 
BED+O patients who accepted and signed the consent forms were 
randomized to receive oxytocin or placebo according to computer-
generated coding. Allocation concealment was achieved by having 
the research pharmacy perform the randomization, package the study 
medication, and maintain the integrity of the blinded information 
throughout the trial, including the statistical evaluation of the results. 
One week after medication discontinuation, patients were submitted to 
a visit aimed at investigating possible disorders due to discontinuation. 
Medications
Medications were supplied by Defiante/Sigma-Tau Industrie 
Farmaceutiche Riunite S.p.A. in packs containing 40 IU of oxytocin 
per ml or placebo. The composition of oxytocin and placebo nasal 
sprays was identical, except for the hormone. Medication kits were 
marked with progressive numbers by the research pharmacy. Each kit 
contained a sealed envelope, marked by the same number of the kit, 
which contained the contents of the packs (oxytocin or placebo). The 
opening would have allowed the investigators to discover the contents 
of the medication spray if necessary without affecting the double-blind 
trial of the other patients. Drugs were kept by the research pharmacy at 
4°C until given to patients.
At the end of the first psychiatric visit, patients received medications 
and recommendations for their nasal administration [13]. Doses of 
placebo and oxytocin were equal to 6 puffs (24 IU), four times a day, 20 
min before each of three meals and before going to bed (96 IU per day). 
After the first week of treatment, the appearance of possible acute side 
effects was evaluated. 
Diet
Participants received a balanced, energy-restricted (-200 kcal/
day of resting energy expenditure) diet (% carbohydrate:fat:protein= 
~ 55:25:20) containing a specific list of appropriate foods compatible 
with their individual preferences.
Outcome measures 
The primary outcomes were the appearance of adverse effects 
and the number of binge eating episodes per week self-registered in 
diaries by participants and confirmed on clinical interview. The diaries 
were provided to participants at the screening evaluation. Participants 
of satiety [9]. More recent trials used the new intranasal formulation 
of oxytocin [13]. This route of administration allows oxytocin to 
penetrate into the central nervous system, likely through olfactory 
epithelial intercellular spaces [13]. In one study, the administration of 
this formulation (24 IU) to individuals of normal weight reduced the 
consumption of palatable food but not hunger-driven eating [10]. In 
another study, the administration of oxytocin nasal spray (24 IU) to 
obese patients, four times a day, approximately 20 min before meals 
and sleep for 8 weeks effectively reduced body weight [11]. In the last 
study, the administration of oxytocin nasal spray (24 IU) to fasting 
healthy subjects, 60 min before meal, reduced caloric intake with a 
preferential effect on fat intake without affecting appetite [12]. 
Oxytocin increases the ability to identify emotions and the empathy 
towards others [14] and may have therapeutic potential for psychiatric 
illnesses that impact social functioning, such as autism, schizophrenia, 
anxiety, and depression [15,16]. 
Some features of BED are similar to those of Substance Use 
Disorders (SUDs) [1]. For example, the urge to consume food and 
the sense of lack of control in BED patients are similar to the urge 
to consume alcohol or other substances of abuse (craving) and the 
sense of lack of control in SUD patients. BED and SUDs also share 
similar neural substrates [17]. The consumption of food (particularly 
foods rich in carbohydrates and fats), as well as the consumption of 
substances of abuse, induce rewarding effects, at least in part, through 
activation of the mesolimbic dopaminergic “reward” system that 
in vulnerable individuals may induce the development of BED and 
SUDs, respectively [17]. The interactions of central oxytocinergic 
neurons with the “reward” system are well documented [18]. In animal 
models, the administration of oxytocin attenuates several behaviors 
related to different substances of abuse (heroin, alcohol, cocaine, and 
psychostimulants) [19,20]. Conversely, the role of oxytocin in the 
treatment of SUDs in humans is unclear as only a few clinical studies 
[21,22] investigated its effects with contrasting results. 
Oxytocin nasal spray may have a role in the treatment of patients 
affected by BED and obesity (BED+O), but no study has been conducted 
to date to investigate its safety and efficacy in these patients. 
Materials and Methods
Participants
Study participants were recruited at the Clinical Nutrition Unit of 
the University Hospital of Cagliari. Patients were eligible for the study 
if they met DSM-5 criteria for BED and had a body mass index (BMI; 
body weight in kg divided by height in m2) ≥ 30 kg/m2. Other inclusion 
criteria were: (1) 21-65 years of age; (2) residence in a location that 
allowed the patient to comply with the scheduled visits; (3) the ability 
to understand the aims of the study, agree to participate in the study, 
and sign the informed consent form. The exclusion criteria were: (1) 
current bulimia or anorexia; (2) current physical diseases (cancer, 
hypertension, heart disease, and cirrhosis) or psychiatric disorders 
(psychotic and personality disorders) that, in the physician’s opinion, 
may constitute a danger for participation in the study; (3) start of 
any pharmacologic treatment within the past 2 months; (4) use of 
psychotherapy and/or pharmacotherapy for BED; (5) abnormal liver 
and/or kidney function; (6) for women of childbearing age, to be 
pregnant, lactating, or not practicing a form of medically accepted 
contraception. The Institutional Review Board at the University of 
Cagliari approved the study protocol (EudraCT number: 2014-002983-
33; authorization no. 12888, 23 July 2014). The study was conducted 
in compliance with the Declaration of Helsinki. All patients signed 
approved written informed consent forms. Patients were enrolled from 
December 2014 through April 2015.
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a physical disease (hypertension) that contraindicated participation in 
the study (N=16), started a new pharmacotherapy within the past 2 
months (N=1), or were lost to follow-up after the screening visit (N=3). 
Seventeen BED+O patients met the entry criteria and were randomized 
to oxytocin (N=8) or placebo (N=9). Sixteen participants (94%) were 
women; 8 were of childbearing age (4 in the oxytocin group and 4 in the 
placebo group) and 8 were post-menopausal or pre-menopausal (3 in 
the oxytocin group and 5 in the placebo group). Three patients (17.6%) 
had mood or anxiety disorders. There were no significant differences 
between the treatment groups at baseline (Table 1). 
were instructed to monitor and record into the diary the binge 
eating episodes, including a detailed description of the type of food 
consumed, the duration of each episode as well as the possible adverse 
effects. Binge eating episodes were defined using DSM-5 criteria. At 
each visit, the diaries were reviewed with participants. Information on 
menstrual cycles and possible uterine side effects were requested to 
female participants of childbearing age. 
Secondary efficacy measures included body weight (BW), BMI, and 
scores achieved on scales used to investigate the severity of BED, craving 
for food, quality of sleep, quality of life, anxiety, and depressive symptoms. 
The severity of BED was evaluated using the Clinical Global Impression-
Severity scale (CGI-S) according to the physician’s opinion [23] and the 
Binge Eating Scale (BES) according to the participant’s opinion [24]. 
The severity of craving for food and quality of life were evaluated using 
visual analogue scales, asking patients to indicate a score from 0-100 mm. 
Quality of life was evaluated using the Short-Form Health Survey (SF-12) 
[25]. Severity of anxiety symptoms was evaluated using the Spielberger 
State Anxiety Inventory (STAI) and severity of depressive symptoms 
using the Zung Self Rating Depression Scale (ZUNG) [26]. Compliance 
was evaluated by counting the returned bottles. At each visit, patients were 
assessed for adverse events, number of binge episodes per week, BW, BMI, 
vital signs, medication compliance, and scores on the CGI-S, BES, SF-12, 
STAI, VAS, and ZUNG.
Statistical analysis
Data were analyzed using IBM SPSS Statistics software (version 21.0). 
We performed an efficacy analysis by comparing changes between 
groups in the outcome variables during the treatment period. The 
analysis assessed the change of the mean of each variable measured 
at each visit during the treatment period (number of binge episodes 
per week, BW, BMI, scores obtained in the CGI-S, BES, SF-12, STAI, 
VAS, and ZUNG). To explore statistical significance, we performed 
a longitudinal repeated-measures random regression analysis with 
a model that included terms for treatment, time, and treatment-by-
time interaction [27]. Time was modeled as a continuous variable, 
with weeks ranging from 0 (baseline) to 8, after beginning treatment 
with oxytocin or placebo. For the analyses of binge frequency the 
logarithmic transformation log ([binge days/week] + 1) was used to 
normalize the data and stabilize the variance. The measure of effect was 
the estimated change in the outcome at week 8. The data were analyzed 
by using a mixed effect model with maximum likelihood estimation. 
Heterogeneous first-order autoregressive covariance structure for 
repeated and random effect was used, as this resulted the best fitting 
model with the lowest standard error of the estimates. 
The analysis was intent-to-treat (ITT), using available observations 
on all participants who completed a baseline evaluation. Data of all 
randomized participants who took at least 1 puff and completed at 
least 1 safety assessment were included in the safety analysis. Data of 
all participants who took at least 1 puff of the medications under study 
and had at least 1 post baseline efficacy assessment were included in the 
efficacy analysis. 
The baseline characteristics of each group were compared by 
using chi-square or Fisher’s exact test for categorical variables and 
independent-samples t tests for continuous variables. A two sided p 
value 0.05 was considered significant.
Results
Of the 69 individuals screened, 52 were not enrolled because they 
did not meet entry criteria (N=17), chose not to participate (N=15), had 
Oxytocin (n=8) Placebo (n=9) p value a
Women, n (%) 7 (87.5) 9 (100.0) 0.4706
Mean age in years (SD) 47.5 (4.5) 49.8 (10.2) 0.5685
Actual mood disorders, n (%) 1 (12.5) 1 (11.1) 1.0000
Actual anxiety disorders, n (%) 0 (0.00) 1 (11.1) 1.0000
BE mean (SD) 4.9 (3.3) 6.0 (2.7) 0.4535
BW mean (SD) 90.8 (23.4) 95.3 (17.2) 0.6554
BMI mean (SD) 34.1 (3.7) 37.6 (5.2) 0.1408
BES  mean (SD) 21.6 (8.4) 23.3 (7.2) 0.6578
CGI–S mean (SD) 4.0 (0.9) 4.9 (1.1) 0.0862
Quality of sleep mean (SD) 75.3 (27.0) 59.7 (36.3) 0.3370
SF-12 mean (SD) 31.5 (6.9) 28.1 (7.2) 0.3399
STAI mean (SD) 48.5 (13.2) 53.0 (14.0) 0.5076
VAS mean (SD) 80.3 (16.6) 81.1 (15.4) 0.9193
ZUNG mean (SD) 41.3 (11.5) 41.3 (12.2) 0.9887
ALT mean (SD) 37.2 (29.6) 24.2 (11.3) 0.2385
AST mean (SD) 21.3 (8.2) 22.8 (9.7) 0.7336
Creatinine mean (SD) 0.8 (0.1) 0.7 (0.2) 0.2531
Urea mean (SD) 33.0 (9.3) 34.8 (11.0) 0.7620
Cholesterol mean (SD) 209.3 (25.4) 209.4 (28.0) 0.9883
HDL Cholesterol mean (SD) 56.4 (9.8) 58.6 (8.1) 0.6242
LDL Cholesterol mean (SD) 124.8 (31.8) 135.7 (17.1) 0.4089
Triglycerides mean (SD) 137.3 (67.7) 107.6 (47.3) 0.3063
Table 1: Baseline characteristics of obese participants with binge eating disorder 
randomly assigned to 8 weeks of double-blind treatment with oxytocin or placebo. 
ALT: Serum Alanine Transaminase Levels
AST: Serum Aspartate Transaminase Levels
BE: Number of episodes of binge eating per week
BES: Binge Eating Scale Score [a 16-itemscale used to assess the severity of 
binge eating behavior with a total score varying from 0 to 46; (non-binging ≤ 17; 
moderate binging=18-26; severe binging ≥ 27)]
BMI: Body Mass Index (weight in kilograms divided by height in m2, normal 
value<25)
BW: Body Weight (in kilograms)
CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of 
severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the 
most severe BED)]
HDL Cholesterol: High-Density Lipoprotein Cholesterol (recommended ranges >60 
mg/dl)
LDL Cholesterol: Low-Density lipoprotein Cholesterol (recommended ranges<100 
mg/dl)
Quality of sleep: Score achieved on a visual analog 100 mm scale (0=the worst 
quality of sleep and 100 mm=the best quality of sleep)
SD: Standard Deviation
SF-12: Score achieved on a 12 item questionnaire used to measure the quality 
of life [total score varies from 12 to 47 (12=the worst quality of life; 47=the best 
quality of life)]
STAI: Score achieved on the Spielberger State Anxiety Inventory scale used to 
measure the severity of anxiety symptoms (total score varies from 40 to 80; scores 
≥40 are indicative of significant anxiety)
VAS: Score achieved on a Visual Analogue Scale of food craving (0=no craving 
and 100 mm=the worst craving)
ZUNG: Score achieved on a 20 item scale used to assess the severity of depressive 
symptoms (total score varies from 20 to 80; scores ≥ 50 are indicative of significant 
depression)
a Chi-square, Fishers exact test or t-tests were used to determine statistical 
differences between the oxytocin and placebo groups
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anxiety and depressive symptoms. Patients of the placebo group 
performed slightly better than patients of the oxytocin group in BMI, 
CGI and STAI scores, although these differences were not significant. 
No difference was also found in the number and typology of side 
The ITT sample for safety analysis included all 17 participants. 
The adverse events are described in Table 2. There was no difference 
in their number between the two groups [6 in the oxytocin group 
(75.0%) and 6 in the placebo group (66.7%), p=1.0000, Fisher’s exact 
test]. One patient of oxytocin group discontinued the trial after 1 week 
of treatment (before the first post-randomization efficacy measure) 
due to erythema. Other three patients of the placebo group developed 
erythema without discontinuing the trial. Two patients of oxytocin 
groups and one patient of the placebo group reported an episode of 
palpitations. No women reported uterine cramping. Only one female 
participant reported an increased sense of uterine pain during a 
menstrual cycle and she was in the placebo group. 
Sixteen participants (7 receiving oxytocin and 9 receiving placebo) 
had at least one post-randomization efficacy measure and constituted 
the ITT sample for efficacy analysis. Among these patients, 13 (81.2%) 
completed the 8 week trial, while the other 3 (18.8%) discontinued 
prematurely after the first month of treatment. All the participants 
who discontinued were in the oxytocin group (p=0.0625, Fisher’s exact 
test). The reasons for withdrawal were unknown (N=1), lack of efficacy 
(N=1), and medical reasons not related to the trial (N=1). 
The observed mean outcome measures at week 8 (for the 13 
completers) along with the analysis of change in outcome measures 
are presented in Tables 3 and 4. Both the longitudinal and end point 
analyses revealed no statistically significant differences between groups 
in the changes in any of the outcomes evaluated. A tendency to different 
effects between the two groups was found for some outcomes (BMI, 
CGI, and STAI scores) with patients of the placebo group showing 
the better results. However, this difference was not significant. A high 
degree of compliance was observed in completing the diaries in both 
the groups, with no difference between them. At study termination, 
7 patients (43.8% of the ITT sample for efficacy analysis) reduced the 
number of binge-eating episodes per week [(4 in the oxytocin group 
(42.9%) and 3 in the placebo group (33.3%); (p=1.0000, Fisher’s exact 
test)] and 5 participants achieved remission of binge eating (31.2%) 
[(1 in the oxytocin group (14.3%) and 4 in the placebo group (44.4%); 
(p=0.3077, Fisher’s exact test)] with no differences between the two 
groups. No participant exhibited significant changes in laboratory 
test results and no disorders due to discontinuation treatment were 
observed (data not shown).
Discussion
As far as our best knowledge, this is the first study to evaluate the 
efficacy and safety of oxytocin nasal spray in BED and obese patients. 
No difference was found between oxytocin and placebo in the number 
of episodes of binge eating, body weight, severity of craving for food, 
Event, n (%) Oxytocin (n=8) Placebo (n=9)
Fisher’s exact 
test
Any 6 (75.0) 6 (66.7) p=1.0000
Sleepness 1 (12.5) 2 (22.2) p=1.0000
Headache 1 (12.5) 2 (22.2) p=1.0000
Uterine pain during menstrual 
cycle 0 (0.0) 1 (11.1) p=1.0000
Nausea 0 (0.0) 1 (11.1) p=1.0000
Erythema 1 (12.5)* 3 (33.3) p=0.5765
Dizzness 0 (0.0) 1 (11.1) p=1.0000
Dry mouth 1 (12.5) 1 (11.1) p=1.0000
Palpitations 2 (25.0) 1 (11.1) p=0.5765
Table 2: Adverse events reported by obese participants with binge eating disorder 
receiving treatment with oxytocin or placebo.
* This patient discontinued the trial due to erythema
  Placebo Oxytocin p
Body weight (kg)
Mean W0 95.3 (17.2) 90.8 (23.4) 0.655
Difference W8 -2.589 (0.894) -1.185 (1.188)  
Difference in 
variation  1.404 (1.487) 0.345
BMI
Mean W0 37.6 (5.2) 34.1 (3.7) 0.141
Difference W8 -1.061 (0.226) -0.363 (0.300)  
Difference in 
variation  0.698 (0.376) 0.073
BED/week 
(Log10)
Mean W0 0.744 (0.080) 0.603 (0.085) 0.454
Difference W8 -0.308 (0.215) -0.150 (0.240)  
Difference in 
variation  0.158 (0.322) 0.633
VAS
Mean W0 81.111 (4.954) 80.313 (5.254) 0.919
Difference W8 -46.667 (7.885)
-42.547 
(10.606)  
Difference in 
variation  4.119 (12.216) 0.758
BES
Mean W0 23.333 (2.313) 21.625 (2.454) 0.658
Difference W8 -12.222 (3.473) -6.027 (4.756)  
Difference in 
variation  6.195 (5.889) 0.305
CGI
Mean W0 4.889 (0.314) 4.000 (0.333) 0.086
Difference W8 -2.444 (0.628) -0.495 (0.881)  
Difference in 
variation  1.949 (1.082) 0.088
SF-12
Mean W0 28.111 (2.278) 31.500 (2.416) 0.340
Difference W8 4.555 (2.104) 0.241 (2.696)  
Difference in 
variation 4.796 (1.082) 0.173
STAI
Mean W0 53 (4.535) 48.500 (4.811) 0.508
Difference W8 -9.444 (4.844) 6.280 (6.512)  
Difference in 
variation  -15.724 (8.116) 0.064
ZUNG
Mean W0 41.333 (3.548) 41.250 (3.763) 0.989
Difference W8 2.222 (5.733) 5.099 (7.992)  
Difference in 
variation  -2.877 (9.836) 0.773
Table 3: Analysis of change in outcome measures. 
BE: Number of episodes of binge eating per week 
BES: Binge Eating Scale score [a 16 item scale used to assess the severity of 
binge eating behavior with a total score varying from 0 to 46 (non-binging ≤ 17; 
moderate binging=18-26; severe binging ≥ 27)] 
BMI: Body Mass Index (weight in kilograms divided by height in m2, normal value<25) 
BW: Body Weight (in kilograms) 
CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of 
severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the 
most severe BED)] 
Quality of sleep, score achieved in a visual analog 100 mm scale (0=the worst 
quality of sleep; 100=the best quality of sleep)
SF-12: Score achieved on a 12-item questionnaire used to measure the quality 
of life [total score varies from 12 to 47 (12=the worst quality of life; 47=the best 
quality of life)] 
STAI: Score achieved on the Spielberger State Anxiety Inventory scale used to 
measure the severity of anxiety symptoms (total score varies from 40 to 80; scores 
≥40 are indicative of significant anxiety) 
VAS: Score achieved on a Visual Analogue Scale of food craving (0=no craving; 
100 mm=the worst craving) 
W0: Week 0 (baseline)
W8: Week 8 (end of treatment, after 8 weeks of treatment) 
ZUNG: Score achieved on a 20-item scale used to assess the severity of depressive 
symptoms (total score varies from 20 to 80; scores ≥ 50 are indicative of significant 
depression)
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effects. A higher rate of patients of oxytocin group reported an episode 
of palpitations. However, this difference did not achieve a statistical 
significance. 
Several factors may have contributed to the lack of efficacy 
observed in the present study. Preclinical studies indicate that oxytocin 
administration decreases food consumption and body weight in obese 
and lean animals [5] but the few clinical studies conducted to date have 
produced conflicting results [9-12]. 
Only one of these studies evaluated the efficacy of oxytocin nasal 
spray in obese subjects finding that it significantly decreased the body 
weight [11]. Despite we used the same schedule of administration and 
dose of this study, in our study oxytocin nasal spray failed to reduce 
body weight. Some methodological differences between the two studies 
may at least in part explain this discrepancy. First, the presence of a 
mental disorder (e.g. BED) was an exclusion criterion in the study by 
Zhang et al. [11] and an inclusion criterion in our study. It has been 
found that the presence of binge eating behavior predicted worse 
weight outcomes in overweight/obese veterans enrolled in weight 
loss treatment [28]. Namely, subjects without binge eating lost almost 
twice as much weight compared to those with binge eating, and high-
frequency binge eating was associated with weight gain. It is possible 
that in our study, the lack of efficacy of oxytocin may be due to the 
presence of BED. Accordingly, BED+O patients may require higher 
doses of oxytocin to reduce body weight than those required by obese 
subjects without BED. 
Another difference between the two studies consists in the energy-
restricted diet that participants received in our study, while in the study 
conducted by Zhang et al. [11], participants did not receive an energy-
restricted diet. It has been observed that oxytocin reduced the intake 
of palatable foods, but was not able to modify food intake in the fasted 
state [10]. Accordingly, the lack of efficacy in reducing food intake 
observed in our study may be due to the energy-restricted diet received 
by participants. It is possible that to reveal possible anorexic effects of 
oxytocin in BED+O patients, subjects should receive a free diet. 
The high response to placebo of BED patients [29] may have also 
contributed to conceal the response to oxytocin. The effects induced by 
oxytocin may vary in individuals affected by different eating disorders. 
For example, a dysregulation of oxytocin secretion has been found in 
anorexic women but not in bulimic women [30,31]. Another study 
found that the administration of oxytocin nasal spray (40 IU) reduced 
food consumption in bulimic women but not in anorexic women [32]. 
The response to oxytocin may also vary according to the schedule 
of administration. In our study, a fixed schedule was used (20 min 
before meals and before going to bed) even if two patients asked to 
modify it into a flexible schedule, “as needed treatment”. Interestingly, 
in humans, increased salivary oxytocin levels last for less than 2 h after 
the administration of oxytocin nasal spray (24 IU, the same dose used 
in our study) [33]. It may be possible that the fixed schedule of oxytocin 
administration could reduce food craving during this 2 h period but 
not after. Further clinical trials should be conducted to investigate the 
potential efficacy of oxytocin for the treatment of BED using flexible 
schedules, according to the need of patients.
Preclinical studies suggest a possible role of oxytocin in the 
treatment of SUDs [19,20]. Considering the analogies between SUDs 
and BED, we hypothesized that the administration of oxytocin nasal 
spray may be able to reduce the severity of craving for food in BED+O 
subjects. However, in our study, oxytocin did not reduce the severity 
of food craving in BED+O subjects. Another study recently failed to 
demonstrate positive effects of oxytocin nasal spray in SUD patients 
[21]. In details, a single administration of oxytocin nasal spray (24 IU) 
increased the severity of craving for cocaine (instead of reducing it) in 
cocaine-dependent patients. 
W0 (n=16) Last Observation a (n=16) W8 b (n=13)
Oxytocin
(n=7)
Placebo
(n=9)
Oxytocin
(n=7)
Placebo
(n=9)
Oxytocin
(n=4)
Placebo
(n=9)
BE mean (SD) 5.1 (3.6) 6.0 (2.7) 4.0 (4.6) 2.4 (3.2) 4.3 (4.7) 2.4 (3.2)
BW mean (SD) 92.5(24.7) 95.3(17.2) 91.4 (24.9) 92.7 (16.8) 102.7 (29.0) 92.7 (16.8)
BMI mean (SD) 34.7 (3.5) 37.6 (5.2) 34.4 (3.7) 36.5 (5.2) 36.2 (3.9) 36.5 (5.2)
BES mean (SD) 21.4 (9.1) 23.3 (7.2) 15.4 (7.3) 11.1 (10.1) 14.8 (9.0) 11.1(10.1)
CGI–S mean (SD) 4.0 (1.0) 4.9 (1.1) 3.1 (1.3) 2.4 (1.9) 3.5 (1.3) 2.4 (1.9)
Quality of sleep mean (SD) 74.6 (29.1) 59.7 (36.3) 75.7 (31.0) 86.7 (21.2) 87.5 (25.0) 86.7 (21.2)
SF-12 mean (SD) 31.9 (7.4) 28.1 (7.2) 31.6 (8.9) 32.9 (7.0) 34.8 (8.2) 32.9 (7.0)
STAI mean (SD) 45.9 (11.8) 53.0(14.0) 50.1 (12.5) 43.6 (18.3) 46.3 (12.0) 43.6 (18.3)
VAS mean (SD) 84.6 (12.1) 81.1 (15.4) 40.7 (24.4) 34.4 (20.2) 37.5 (18.9) 34.4 (20.2)
ZUNG mean (SD) 42.3 (12.0) 41.3 (12.2) 43.6 (10.3) 43.6 (20.2) 39.5 (7.9) 43.6 (20.2)
Table 4: Efficacy measures. 
BE: Number of episodes of binge eating per week 
BES: Binge Eating Scale score [a 16 item scale used to assess the severity of binge eating behavior with a total score varying from 0 to 46 (non-binging ≤ 17; moderate 
binging=18-26; severe binging ≥ 27)] 
BMI: Body Mass Index (weight in kilograms divided by height in m2, normal value<25); 
BW: Body Weight (in kilograms) 
CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the most 
severe BED)] 
Quality of sleep, score achieved on a visual analog 100 mm scale (0=the worst quality of sleep; 100=the best quality of sleep) 
SF-12: Score achieved on a 12-item questionnaire used to measure the quality of life [total score varies from 12 to 47 (12=the worst quality of life; 47=the best quality of life)] 
STAI: Score achieved in the Spielberger State Anxiety Inventory scale used to measure the severity of anxiety symptoms (total score varies from 40 to 80; scores ≥40 are 
indicative of significant anxiety) 
VAS: Score achieved on a Visual Analogue Scale of food craving (0=no craving; 100 mm=the worst craving) 
W0: Week 0 (baseline)
W8: Week 8 (end of treatment, after 8 weeks of treatment)  
ZUNG: Score achieved on a 20-item scale used to assess the severity of depressive symptoms (total score varies from 20 to 80; scores ≥ 50 are indicative of significant 
depression)
a Last observation end point was defined using last observation carried forward
b Week 8 end point was available for only those participants who completed the study
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Another study showed that oxytocin nasal spray did not induce 
beneficial effects in individuals with Prader-Willi syndrome (PWS) 
[34]. This genetic syndrome is characterized by complex physical, 
behavioral, and intellectual abnormalities, and hyperphagia [35]. If 
food consumption is left unmanaged, individuals with PWS develop 
obesity. It has been hypothesized that hyperphagia might be due to 
oxytocin deficiency found in PVN of patients affected by PWS [34]. 
Accordingly, it has been hypothesized that oxytocin nasal spray may 
reduce food consumption and body weight in patients affected by PWS. 
Conversely, its administration (36-80 IU daily, divided into two daily 
administrations) did not reduce food consumption and body weight in 
these individuals [34]. 
Other studies reported unattended results [36-38]. For instance, 
oxytocin nasal spray resulted to be anxiogenic instead of anxiolytic 
in depressed patients [36], increased the perception of social stress 
instead of decreased it [37], and did not reduce anxiety and depressive 
symptoms in fibromyalgic patients [38]. It has been proposed that the 
effects induced by oxytocin may also vary according to the social or 
behavioral context [39].
Another factor that may have contributed to the unattended 
results found in the present study may be due to the large number of 
female participants recruited. Recent studies have suggested that the 
response to oxytocin nasal spray may differ between male and female 
participants. A recent meta-analysis of imaging studies found that in 
certain brain regions, oxytocin nasal spray induces almost opposite 
effects in men and women during the processing of different tasks [40]. 
The majority of preclinical studies conducted to investigate the 
efficacy of oxytocin in reducing food intake and body weight used 
mostly male animals [8]. Also clinical studies conducted to investigate 
the efficacy of oxytocin nasal spray in nutrition recruited mainly male 
participants [9-12]. Interestingly, the only male participant (who 
also received oxytocin) recruited by the current study had a positive 
response to medical treatment. Another study found that the daily 
administration of oxytocin nasal spray (40 IU) for four months did not 
modify BMI of 32 schizophrenic patients, mainly constituted by male 
participants (27 man and 5 women) [41]. Globally, these data suggest 
that further studies aimed at investigating the effects of oxytocin nasal 
spray in reducing food consumption and/or body weight should 
evaluate possible sex differences to these effects. But only recently, 
possible sex differences in the response to oxytocin as well as among 
BED patients are under investigation [42-44].
This study has several limitations, one being the small number of 
subjects recruited. This number was in part justified by the need to 
investigate the safety of oxytocin in a population of patients at high 
risk of possible complications, such as BED+O patients. One patient of 
oxytocin group discontinued the trial after 1 week of treatment due to 
erythema, but other three patients of the placebo group developed the 
same side effect although they did not discontinue the trial. Accordingly, 
this side effect does not seem to be related to the presence of oxytocin in 
the nasal spray formulation. In addition, no participant required higher 
doses of oxytocin during the study, suggesting the lack of craving for 
this medication. Oxytocin nasal spray resulted to be devoid of uterine 
side effects in female participants of childbearing age. Furthermore, no 
side effect was observed at the end of the pharmacological treatment 
(one week after treatment discontinuation), suggesting that the 
interruption of an 8 week oxytocin treatment did not induce health 
problems in the sample of BED+O patients who completed the study.  
In conclusion, despite the rationale for evaluating the effects in 
BED+O patients, the present study showed that a 8 week treatment 
with oxytocin nasal spray did not reduce craving for food and body 
weight but resulted to be safe in this sample of patients, the majority 
of whom were women. Possible reasons for the lack of efficacy of 
oxytocin nasal spray include the almost exclusively presence of female 
participants, the energy-restricted diet, the dose, and the fixed schedule 
of administration. Globally, these results suggest that future studies 
aimed at investigating the efficacy of oxytocin nasal spray in obese 
patients with BED should recruit adequate number of female and male 
participants to investigate possible gender differences, permit a free 
diet, and administer higher doses of oxytocin, in a flexible schedule. 
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